|Day Low/High||24.46 / 24.50|
|52 Wk Low/High||2.93 / 24.50|
Shares of several companies that have developed hepatitis C, or HCV, treatments are rising after one such company, Idenix, agreed to be acquired by Merck.
Merck is making an all-cash $3.85 billion tender offer for Cambridge, Mass.-based Idenix Pharmaceuticals in a strategic bid to strengthen Merck's hepatitis C drug program.
Levi & Korsinsky is investigating the Board of Directors of Idenix Pharmaceuticals, Inc.
Johnson & Johnson and Abbvie were both reportedly interesting in buying Idenix but lost out to Merck, reports CNBC. Achillion shares are up almost 30% to $TK Monday as investors bet the losers in the Idenix sweepstakes may move on to the next target.
With Gilead Sciences already marketing the hepatitis C pill Sovaldi and competition from Abbvie-Enanta Pharma and Bristol-Myers Squibb close behind, a lot of investors believed the hepatitis C drug race had transitioned to marketing and away from M&A. But Merck chief scientitist Roger Perlmutter is no dummy, so his decision to spend almost $4 billion on Idenix says the hepatitis C treatment market may have a much longer tail than many believed.
In trading on Wednesday, shares of Idenix Pharmaceuticals Inc crossed above their 200 day moving average of $5.42, changing hands as high as $5.52 per share. Idenix Pharmaceuticals Inc shares are currently trading up about 5.8% on the day.
In trading on Friday, shares of Idenix Pharmaceuticals Inc crossed below their 200 day moving average of $5.26, changing hands as low as $5.01 per share. Idenix Pharmaceuticals Inc shares are currently trading off about 6.8% on the day.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Investors in Idenix Pharmaceuticals Inc saw new options become available this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the IDIX options chain for the new May 17th contracts and identified one put and one call contract of particular interest.
These under-$10 stocks are within range of triggering breakout trades.
Granted European Patent Covering 2'-Methyl-2'-Fluoro Nucleosides for Treating Hepatitis C Virus
The No. 1 stock on this list has more than half its float short.
The top 10 open-market insider purchases and sales filed at the SEC Tuesday.
Idenix is doubling down on hepatitis C drug development and litigation against Gilead Sciences, CEO Ron Renaud says.
Trade-Ideas LLC identified Idenix Pharmaceuticals (IDIX) as a "perilous reversal" (up big yesterday but down big today) candidate
It's still pre-dawn in San Francisco, a few hours from the start of the J.P. Morgan Healthcare Conference, but that hasn't stopped biotech and drug companies from dumping a ton of news and announcements into the market. Here's a brief look at what's making headlines this morning:
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.